XML 67 R56.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 30, 2023
Jun. 30, 2023
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Disaggregation Of Revenue [Line Items]              
Net product revenue     $ 131,454,000 $ 1,323,000 $ 132,584,000 $ 2,010,000  
License agreement receivable   $ 25,000,000 25,000,000   25,000,000   $ 0
Deferred revenue, current portion   3,229,000 3,229,000   3,229,000   0
Deferred revenue, long term   1,140,000 1,140,000   1,140,000   $ 0
Product Revenue, Net              
Disaggregation Of Revenue [Line Items]              
Net product revenue     468,000 1,323,000 1,598,000 $ 2,010,000  
GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
License agreement receivable   25,000,000.0 25,000,000.0   25,000,000.0    
License agreement contract asset   19,300,000 19,300,000   19,300,000    
License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Success-based development milestones receivable $ 45,000,000.0            
Revenue recognized     500,000        
Non refundable upfront payment received 90,000,000            
Total transaction price 136,100,000            
Payment of transaction price 90,000,000.0            
License transfer performance obligation revenue 130,100,000   130,100,000   130,100,000    
Research and development activity 4,800,000            
Ongoing clinical and preclinical studies 1,200,000            
License Agreement | GlaxoSmithKline Intellectual Property | License Transfer              
Disaggregation Of Revenue [Line Items]              
Revenue recognized         $ 400,000    
Exclusive License And Collaboration Agreement              
Disaggregation Of Revenue [Line Items]              
Revenue recognized     $ 0 $ 0      
Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit 77,500,000            
Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit 65,000,000            
Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit 50,000,000            
Successful Completion of Mario Study | License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Success-based development milestones receivable 10,500,000            
Performance-based development milestones receivable   $ 25,000,000.0          
Maximum | License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Regulatory milestone payments receivable 70,000,000            
Commercial milestones payments receivable 115,000,000            
Sales milestone payments receivable 242,500,000            
Success-based development milestones receivable 75,500,000            
Maximum | Achivement of Three Interim Milestone of Ongoing Mario Study | License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Success-based development milestones receivable $ 65,000,000            
Sales Revenue Net | Customer Concentration Risk | Wholesaler One              
Disaggregation Of Revenue [Line Items]              
Percentage of gross revenue         46.00%    
Sales Revenue Net | Customer Concentration Risk | Wholesaler Two              
Disaggregation Of Revenue [Line Items]              
Percentage of gross revenue         26.00%    
Sales Revenue Net | Customer Concentration Risk | Wholesaler Three              
Disaggregation Of Revenue [Line Items]              
Percentage of gross revenue         25.00%